Latest Ratios: P/E Ratio -2.6x · EV/EBITDA N/A · ROE -134.9%. (2011–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $21M | $12M | $9M | $17M | $24M | $21M | $9M | $25M | $24M | $33M | $34M |
| Enterprise Value | $16M | $7M | $5M | $14M | $20M | $13M | $7M | $21M | $21M | $25M | $17M |
| P/E Ratio → | -2.62 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 30.45 | 17.54 | 12.62 | 20.58 | 27.88 | 27.87 | 4.65 | 6.42 | 28.49 | 194.42 | 203.45 |
| P/B Ratio | 3.78 | 2.17 | 1.50 | 3.73 | 1.65 | 3.50 | 3.87 | 8.13 | 7.88 | 8.51 | 3.21 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 10.54 | 6.91 | 16.98 | 22.88 | 17.12 | 3.36 | 5.47 | 24.35 | 146.56 | 100.76 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -1206.2% | -1206.2% | -1103.0% | -1246.4% | -1505.5% | -1853.1% | -590.9% | -141.7% | -873.1% | -5093.7% | -3894.6% |
| Net Profit Margin | -1169.1% | -1169.1% | -1027.5% | -1255.9% | -1476.6% | -1892.9% | -621.3% | -172.0% | -588.2% | -4069.3% | -2912.3% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -134.9% | -134.9% | -142.5% | -107.9% | -123.1% | -339.2% | -462.7% | -216.5% | -143.4% | -96.3% | -55.5% |
| ROA | -82.5% | -82.5% | -79.2% | -68.9% | -84.6% | -163.2% | -156.6% | -83.3% | -55.2% | -49.7% | -34.5% |
| ROIC | -448.3% | -448.3% | -345.2% | -129.7% | -241.1% | — | — | — | — | — | — |
| ROCE | -108.1% | -108.1% | -111.1% | -83.1% | -99.6% | -214.9% | -246.7% | -99.6% | -107.7% | -73.5% | -52.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.87 | -0.68 | -0.65 | -0.30 | -1.35 | -1.07 | -1.20 | -1.15 | -2.09 | -1.62 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -580.71 | -580.71 | -585.36 | -631.04 | -713.44 | -36.53 | -26.80 | -300.78 | -263.42 | -315.66 | -11.37 |
Net cash position: cash ($5M) exceeds total debt ($104000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.38 | 4.38 | 4.90 | 3.66 | 7.35 | 7.41 | 2.18 | 2.53 | 3.82 | 4.04 | 9.86 |
| Quick Ratio | 4.38 | 4.38 | 4.90 | 3.68 | 7.37 | 7.41 | 2.40 | 2.53 | 5.66 | 4.04 | 10.21 |
| Cash Ratio | 3.84 | 3.84 | 4.42 | 3.19 | 7.01 | 6.57 | 0.84 | 1.25 | 1.95 | 3.24 | 9.52 |
| Asset Turnover | — | 0.07 | 0.07 | 0.09 | 0.04 | 0.08 | 0.25 | 0.48 | 0.11 | 0.02 | 0.01 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 41.70 | 38.32 | 21.18 | 20.54 | 8.61 | 114.42 | — | — | 47.02 | 137.37 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $7M | $4M | $3M | $2M | $1M | $286366 | $129674 | $108417 | $92308 | $76510 |
Liquidity and dilution risk
According to recent market data, CANF trades at a price-to-sales ratio of 29.59, a multiple that appears disconnected from fundamental performance and suggests investors are pricing in speculative binary outcomes rather than current revenue, which remains negligible and highly volatile due to its reliance on milestone payments.
The elevated P/S ratio relative to the broader biotech sector indicates that the market is assigning value to the potential of the A3AR platform rather than existing cash flows. This valuation is inherently fragile, as any delay in clinical milestones or regulatory setbacks could lead to a rapid compression of multiples as the market recalibrates for dilution risk.
Based on reported financial statements, the company's ROIC has trended into negative territory, reaching -2.1% in 2024Q4, which highlights a persistent inability to generate returns on invested capital as research expenditures continue to outpace the sporadic and non-recurring revenue generated from licensing agreements.
The negative ROIC trend underscores the structural challenge of a pre-commercial biotech firm where capital is consumed by long-cycle R&D without immediate commercialization. Investors should monitor whether the company can achieve a positive inflection point in capital efficiency as it approaches potential regulatory approval for its lead assets.
As reported in recent SEC filings, the company's current ratio has fluctuated, settling at 3.60 in 2025Q2, yet this metric may provide a false sense of security given the high cash burn rate and the absence of recurring revenue to support ongoing operational requirements.
While the current ratio appears adequate on the surface, the lack of liquid, recurring cash inflows means the company remains highly dependent on external financing. The rapid erosion of the asset base suggests that the current liquidity position is insufficient to sustain long-term operations without further dilutive capital raises.
Based on an analysis of the business model, the price-to-sales ratio is the most commonly misapplied metric for CANF, as it obscures the reality that current revenue is derived from one-time milestones rather than sustainable, recurring product sales or predictable market demand.
Using P/S to value this firm ignores the 'lumpiness' of milestone-based income, which does not reflect the underlying health of the commercial pipeline. Analysts should instead focus on the cash runway and the probability-adjusted net present value of the clinical assets to better assess the firm's true economic worth.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CANF stock.
Can-Fite BioPharma Ltd.'s current P/E ratio is -2.6x. This places it at the 50th percentile of its historical range.
Can-Fite BioPharma Ltd.'s return on equity (ROE) is -134.9%. The historical average is -215.0%.
Based on historical data, Can-Fite BioPharma Ltd. is trading at a P/E of -2.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Can-Fite BioPharma Ltd. has 100.0% gross margin and -1206.2% operating margin.